Matinas BioPharma Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $1.1M | $3.2M | $33,000 |
| Operating income | -$7.0M | -$24.6M | -$23.8M | -$24.6M | -$24.7M |
| Cash from operations | -$7.0M | -$15.9M | -$15.3M | -$19.2M | -$15.2M |
| Capital expenditure | — | — | $218,000 | $892,000 | $260,000 |
| Free cash flow | — | — | -$15.5M | -$20.0M | -$15.5M |
| Impairments | — | $1.3M | — | $0 | $0 |
| Total assets | $7.2M | $12.6M | $25.1M | $44.8M | $61.3M |
| Total liabilities | $2.4M | $5.1M | $5.9M | $8.2M | $8.8M |
Shares outstanding 6.4M · Free float 92.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.